Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1596

1.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

2.

Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.

Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, Brooks DJ, Hinz R.

Neuroimage. 2013 Apr 15;70:423-33. doi: 10.1016/j.neuroimage.2012.12.014. Epub 2012 Dec 20.

PMID:
23261639
3.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062. Epub 2009 Mar 31.

4.

Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.

Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ, Hoge JA, Ziolko SK, DeKosky ST, Klunk WE.

J Neurosci Methods. 2008 Jul 30;172(2):277-82. doi: 10.1016/j.jneumeth.2008.05.005. Epub 2008 May 16.

5.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

PMID:
21310725
6.

Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.

Waragai M, Okamura N, Furukawa K, Tashiro M, Furumoto S, Funaki Y, Kato M, Iwata R, Yanai K, Kudo Y, Arai H.

J Neurol Sci. 2009 Oct 15;285(1-2):100-8. doi: 10.1016/j.jns.2009.06.005. Epub 2009 Jun 23.

PMID:
19552926
7.

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ.

Neurology. 2009 Sep 8;73(10):754-60. doi: 10.1212/WNL.0b013e3181b23564. Epub 2009 Jul 8.

8.

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2007 May 8;68(19):1603-6.

PMID:
17485647
9.

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.

Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ.

J Neurosci. 2013 Mar 27;33(13):5553-63. doi: 10.1523/JNEUROSCI.4409-12.2013.

10.

Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.

Jiménez-Bonilla JF, Banzo I, De Arcocha-Torres M, Quirce R, Martínez-Rodríguez I, Lavado-Pérez C, Bravo-Ferrer Z, Rodríguez-Rodríguez E, Sánchez-Juan P, Carril JM.

Nucl Med Commun. 2016 Nov;37(11):1189-96. doi: 10.1097/MNM.0000000000000569.

PMID:
27341411
11.

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.

Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.

PMID:
24681664
12.

The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.

Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ.

Alzheimers Dement. 2013 Nov;9(6):687-698.e1. doi: 10.1016/j.jalz.2012.10.012. Epub 2013 Mar 7.

13.

Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.

Bourgeat P, Chételat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Salvado O; AIBL Research Group.

Neurology. 2010 Jan 12;74(2):121-7. doi: 10.1212/WNL.0b013e3181c918b5.

PMID:
20065247
14.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

PMID:
22628162
15.

Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.

Ossenkoppele R, Zwan MD, Tolboom N, van Assema DM, Adriaanse SF, Kloet RW, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN.

Brain. 2012 Jul;135(Pt 7):2115-25. doi: 10.1093/brain/aws113. Epub 2012 May 3.

PMID:
22556189
16.

Amyloid imaging in mild cognitive impairment subtypes.

Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST.

Ann Neurol. 2009 May;65(5):557-68. doi: 10.1002/ana.21598. Erratum in: Ann Neurol. 2009 Jul;66(1):123. DeKoskym, Steven T [corrected to De-Kosky, Steven T].

17.

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2016 May;139(Pt 5):1551-67. doi: 10.1093/brain/aww027. Epub 2016 Mar 8.

18.

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013. Epub 2010 Apr 10.

PMID:
20385246
19.

Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.

Racine AM, Adluru N, Alexander AL, Christian BT, Okonkwo OC, Oh J, Cleary CA, Birdsill A, Hillmer AT, Murali D, Barnhart TE, Gallagher CL, Carlsson CM, Rowley HA, Dowling NM, Asthana S, Sager MA, Bendlin BB, Johnson SC.

Neuroimage Clin. 2014 Feb 19;4:604-14. doi: 10.1016/j.nicl.2014.02.001. eCollection 2014.

20.

(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J.

Cochrane Database Syst Rev. 2014 Jul 23;(7):CD010386. doi: 10.1002/14651858.CD010386.pub2. Review.

PMID:
25052054

Supplemental Content

Support Center